BCL2L1 and Thrombocytopenia: However, AstraZeneca has recently developed AZD0466, a dual Bcl-2/Bcl-xL inhibitor conjugated to a PEGylated poly-lysine dendrimer, that has reduced the cardiovascular issues and thrombocytopenia seen with other Bcl-2/Bcl-xL inhibitors [47–49].